Patents
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
09/2002
09/06/2002WO2002068643A1 Nomuraeae rileyi-origin ecdysteroid 22-oxidase and molt hormone inactivation system with the use of the same
09/06/2002WO2002068635A2 Methods of inhibiting expression of a target gene in mammalian cells
09/06/2002WO2002068633A2 Compositions and methods relating to lung specific genes and proteins
09/06/2002WO2002068629A2 Dna constructs for cytoplasmic and mithochondrial expression and methods of making and using same
09/06/2002WO2002068627A2 Vector constucts
09/06/2002WO2002068617A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/06/2002WO2002068614A2 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
09/06/2002WO2002068585A2 Tip39 polypeptides
09/06/2002WO2002068470A2 Interferon-alpha induced gene
09/06/2002WO2002068465A2 Novel p53-inducible protein
09/06/2002WO2002068444A1 Ttk in diagnosis and as a therapeutic target in cancer
09/06/2002WO2002067996A2 Beta-endorphin/crf gene therapy for locally combating pain
09/06/2002WO2002067990A1 Polynucleotide formulation for enhanced intracellular transfer
09/06/2002WO2002067979A1 Method of improving the growth performance of an animal
09/06/2002WO2002067971A2 Use of endostatin in the treatment of ocular neovascularization
09/06/2002WO2002067970A1 TRYPTOPHANYL-tRNA SYNTHETASE DERIVED POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
09/06/2002WO2002067861A2 Oncolytic adenoviral vectors
09/06/2002WO2002048182A3 Interferon-alpha induced gene
09/06/2002WO2002040517A3 M. tuberculosis chaperonin 60.1 and uses thereof
09/06/2002WO2002040037A3 M. tuberculosis chaperonin 60.1 and uses thereof
09/06/2002WO2002036771A3 Imaging, diagnosis and treatment of disease
09/06/2002WO2002010217A3 Endothelial cell expression patterns
09/06/2002WO2001095946A3 Combination product for carrying out a cytotoxic treatment in a mammal
09/06/2002WO2001092565A3 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription
09/06/2002WO2001092562A3 Inhibiting retroviral integration by targeting the atm pathway
09/06/2002WO2001085932A3 Immunogenic polypeptides encoded by mage minigenes and uses thereof
09/06/2002WO2001085785A3 Ph domain-interacting protein
09/06/2002WO2001075068A9 Secreted proteins and polynucleotides encoding them
09/06/2002WO2001073093A3 Cell-specific adenovirus vectors comprising an internal ribosome entry site
09/06/2002WO2001072822B1 Genes involved in intestinal inflammatory diseases and use thereof
09/06/2002WO2001064738A3 Heparin-binding amino acid sequences derived from human proteins facilitating penetration of a substance of interest into cells and/or cell nuclei
09/06/2002WO2001058915A8 Human g-protein chemokine receptor (ccr5) hdgnr10
09/06/2002WO2001032614A9 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
09/06/2002WO2001031021A9 Multiple sclerosis-related superantigen
09/06/2002WO2001018546A9 Screening for inhibitors of 'paired helical filaments'
09/06/2002WO2001018035A9 Muc-1 derived peptides
09/06/2002WO2001014581A9 Hdac4 and hdac5 in the regulation of cardiac gene expression
09/06/2002WO2001012236A9 Methods, compositions and kits for promoting recovery from damage to the central nervous system
09/06/2002WO2001007627A9 Drosophila recombination-associated protein and methods for use
09/06/2002WO2001007059A9 Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
09/06/2002WO2001005945A9 Packaging systems for human recombinant adenovirus to be used in gene therapy
09/06/2002WO2001004334A9 Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 coxsacki adenovirus receptor (car)
09/06/2002WO2000078955A9 Epithelial cell growth inhibitors
09/06/2002WO2000067761A9 Compositions and methods for identifying antigens which elicit an immune response
09/06/2002CA2674673A1 Modified and stabilized gdf propeptides and uses thereof
09/06/2002CA2439492A1 Tri-hybrid melanoma antigen
09/06/2002CA2439335A1 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
09/06/2002CA2439185A1 Vector constructs
09/06/2002CA2439116A1 Method of improving the growth performance of an animal
09/06/2002CA2439115A1 Novel oncolytic adenoviral vectors
09/06/2002CA2438710A1 <i>nomuraeae rileyi</i>-origin ecdysteroid 22-oxidase and molt hormone inactivation system with the use of the same
09/06/2002CA2438696A1 Polynucleotide formulation for enhanced intracellular transfer
09/06/2002CA2438273A1 Tryptophanyl-trna synthetase derived polypeptides useful for the regulation of angiogenesis
09/06/2002CA2437898A1 Interferon-alpha induced gene
09/06/2002CA2437218A1 Modified and stabilized gdf propeptides and uses thereof
09/06/2002CA2434690A1 Proteins, polynucleotides encoding them and methods of using the same
09/06/2002CA2432029A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/06/2002CA2430702A1 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
09/05/2002US20020123634 Asymmetric derivatives of furamidines; contacting the sample DNA with above compound
09/05/2002US20020123614 Modified polypeptides stabilized in a desired conformation and methods for producing same
09/05/2002US20020123611 Membrane polypeptides for use in treatment of kidney defects
09/05/2002US20020123481 C-fos induced growth factor (FIGF) and DNA encoding same
09/05/2002US20020123478 Synthetic transfection vectors
09/05/2002US20020123477 Contacting a target cell with DNA-damaging agent; removing DNA-damaging agent from target cell; transferring transgene into target cell between about 1-3 days after removing DNA-damaging agent
09/05/2002US20020123476 For treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences
09/05/2002US20020123473 For therapy of asthma
09/05/2002US20020123471 Useful as a gene transfer vehicle for gene therapy, i.e. of the central nervous system
09/05/2002US20020123458 Endostatin protein and fragments thereof
09/05/2002US20020123147 Gene transfer with adenoviruses having modified fiber proteins
09/05/2002US20020123146 Cell culture; for use as tool in gene therapy and cel packaging
09/05/2002US20020123141 Recovering embryonic-like stem cells from a placenta; obtain placenta, drain cord blood, flush placenta with anticoagulant solution, recover cells
09/05/2002US20020123138 Human VNO receptor (R1)
09/05/2002US20020123119 Nucleotide sequences coding enzymatic polypeptide for use in screening bactericides and for treatment and prevention of infections
09/05/2002US20020123106 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of nervous system disorders
09/05/2002US20020123104 Human slit polypeptide and polynucleotides encoding same
09/05/2002US20020123102 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of thyroid defcets
09/05/2002US20020123099 Highly expressible genes
09/05/2002US20020123093 Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia
09/05/2002US20020123083 Nucleic acid endocing growth factor protein
09/05/2002US20020123067 Chlamydia antigens and corresponding DNA fragments and uses thereof
09/05/2002US20020123047 dexB
09/05/2002US20020122819 Preparing invaginated liposomes by heating 1,2-bis(oleoyloxy) -3-(trimethylammonio)- propane and cholesterol or a derivative; sonicating; and extruding lipid components sequentially through filters of decreasing pore size
09/05/2002US20020122802 Diagnosis and treatment of malignant neoplasms
09/05/2002US20020122793 Heparinase III and uses thereof
09/05/2002US20020122789 Modified by an insertion nucleic acid coding for a polypeptide sequence to be expressed in said muscle cells, are used to obtain a drug for treating muscle cell diseases or diseases
09/05/2002US20020122788 Long-term expression of gene products by transforming muscle cells
09/05/2002DE10109898A1 Lipide mit veränderlicher Ladung Lipids with variable charge
09/05/2002DE10109780A1 Episomale Vektoren enthaltend Matrix-Anheftungsregionen zur zellspezifischen Genexpression Episomal vectors containing matrix attachment regions of cell-specific gene expression
09/05/2002DE10106835A1 Signaltransduktionsproteine 15B3, 15B3-1 und 15B3-2 und zugrundeliegende DNA-Sequenzen Signal transduction 15B3, 15B3-1 and 15B3-2 and underlying DNA sequences
09/04/2002EP1236800A2 Nucleic acids encoding interferon alpha 2, containing single nucleotide polymorphisms and methods of use thereof
09/04/2002EP1236799A2 Human nucleic acid sequences derived from breast tumor tissue
09/04/2002EP1236477A2 A formative agent of protein complex
09/04/2002EP1236473A2 Self-assembling polynucleotide delivery system
09/04/2002EP1235936A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
09/04/2002EP1235934A2 Screening method for candidate drugs
09/04/2002EP1235924A1 Antisense modulation of rank expression
09/04/2002EP1235922A2 Excipient system that contains coating substances with enzymatically removable side-groups
09/04/2002EP1235915A2 Transgenic mammals into which a period 1 promoter that confers rhythmical expression has been introduced
09/04/2002EP1235914A2 Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
09/04/2002EP1235912A2 Tumour-specific vector for gene therapy